GLP-1 Side Effects: What the Trials and FDA Labels Actually Report

Every GLP-1 label carries the same warnings, and every provider glosses over them at roughly the same rate. Here is what the pivotal trials and the FDA's own labeling actually report — not the marketing summary, the numbers underneath it — so you can judge whether a provider's monitoring plan is built for the real risk profile or just for the sales page.

The GI side effects are real, common, and usually the reason people quit

Nausea, diarrhea, vomiting, and constipation are the headline adverse reactions on every GLP-1 label, and they are the reason most people who stop treatment stop. In STEP-1, gastrointestinal events caused 4.5% of the semaglutide group to discontinue treatment, versus 0.8% on placebo¹. In SURMOUNT-1, the same pattern held at every tirzepatide dose: discontinuations ran 4.3% at 5 mg, 7.1% at 10 mg, and 6.2% at 15 mg, against 2.6% on placebo — adverse events, mostly gastrointestinal, occurring primarily during dose escalation². Read plainly: GI side effects are not a rare footnote, they are the single most common reason a GLP-1 prescription doesn't make it to the maintenance dose, which is exactly why a slow, monitored titration schedule belongs in a provider's clinical-oversight score, not just its dosing chart.

The boxed warning, in the FDA's own words

Every approved GLP-1 — Wegovy, Zepbound, Ozempic, and Mounjaro alike — carries the strongest label a drug can carry: a boxed warning that the drug "causes thyroid C-cell tumors" in rodents at clinically relevant exposures, that human relevance "has not been determined," and that the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2³⁴. That contraindication is not a formality. It is a question a real intake has to ask and a rubber-stamp form does not.

Pancreatitis and gallbladder disease are on the label — and gallbladder risk is now quantified

Both the Wegovy and Zepbound labels flag acute pancreatitis as an observed risk and note the drugs have not been studied in patients with a prior history of it³⁴. Gallbladder disease is more than a label mention: a 2022 meta-analysis of 76 randomized trials covering more than 103,000 patients found GLP-1 receptor agonist use raised the risk of gallbladder or biliary disease overall (relative risk 1.37), with the risk concentrated in trials that used weight-loss dosing specifically — a relative risk of 2.29 in that subgroup, versus 1.27 in diabetes and other-disease trials⁵. Rapid weight loss itself is a known trigger for gallstones, which is one reason the size and pace of a dose escalation is not just a comfort question.

Diabetic retinopathy: a signal specific to people who already have it

In SUSTAIN-6, the long-term semaglutide cardiovascular trial in people with type 2 diabetes, retinopathy complications — vitreous hemorrhage, blindness, or conditions requiring treatment — occurred significantly more often on semaglutide than placebo (hazard ratio 1.76)⁶. Both the Wegovy and Zepbound labels now instruct monitoring patients with a history of diabetic retinopathy for progression³⁴. This is not a reason to avoid the drug class; it is a reason a provider should be asking about your eye history before you start, not after.

What this means before surgery or a procedure

Because GLP-1s slow gastric emptying by design, a 2024 clinical-pharmacology review in *Anaesthesia* walked through the peri-operative implications: delayed emptying can leave more stomach contents than expected at the time of anesthesia, raising aspiration risk during sedation⁷. If you take a GLP-1 and have surgery, a dental procedure, or any sedation scheduled, tell the team beforehand — it is a five-second disclosure that a good provider should be prompting you to make, not something you have to remember to volunteer.

Compounded vials add a risk the pivotal trials never tested: the dose itself

Every risk above assumes the dose in the syringe is the dose on the label. Compounded semaglutide often isn't dispensed that way. A 2023 case series published in the *Journal of the American Pharmacists Association* documented three real poison-control calls after patients self-administered compounded semaglutide obtained from compounding pharmacies and a medical spa — two of them tenfold dosing errors, with symptoms including days of nausea, vomiting, and abdominal pain⁸. The root cause in each case was the same: compounded vials lack the built-in safety features of a manufactured pen, dosing gets tracked in milliliters or "units" instead of milligrams, and one patient received a vial and syringes with no pharmacist counseling on how to draw up the dose at all⁸. That is a fulfillment failure, not a drug failure — and it is exactly the kind of gap our rule on when compounded GLP-1 is even lawful to sell and our legitimacy checklist are built to catch before you're the one holding the syringe.

Where this belongs in a provider's grade

None of this argues against GLP-1 therapy — the trial evidence for weight loss and, increasingly, for benefits beyond the scale is strong. It argues for real supervision. That is why clinical oversight and labs-and-monitoring together account for 35% of the WeighScore: a provider that screens for the MTC/MEN2 contraindication, asks about retinopathy and gallbladder history, flags upcoming procedures, and counsels every compounded-vial patient on exact dosing is doing the safety work the label requires. One that skips straight to checkout is not, regardless of what the landing page promises. Our six-point checklist puts "real clinical oversight" first for exactly this reason.

The honest bottom line

Side effects on a GLP-1 are common, mostly gastrointestinal, and usually manageable with a properly paced titration — but the rarer risks are specific enough that they should shape who prescribes your medication and how closely they watch you, not just which molecule you pick. See how graded providers compare on oversight and monitoring in our reviews and comparisons. None of this is medical advice; a licensed clinician who knows your full history should be the one weighing these risks against the benefit for you.